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A characteristic feature of idiopathic pulmonary fibrosis (IPF) is accumulation of apoptotic
resistant fibroblasts/myofibroblasts in the fibroblastic foci. As caveolin (Cav)-null mice
develop pulmonary fibrosis (PF), we hypothesized that the participating fibroblasts display
an apoptosis-resistant phenotype. To test this hypothesis and identify the molecular
mechanisms involved we isolated lung fibroblasts from Cav-null mice and examined
the expression of several inhibitors of apoptosis (IAPs), of c-FLIP, of Bcl-2 proteins
and of the death receptor CD95/Fas. We found significant increase in XIAP and c-FLIP
constitutive protein expression with no alteration of Bcl-2 and lower levels of CD95/Fas.
The isolated fibroblasts were then treated with the CD95/Fas ligand (FasL) to induce
apoptosis. While the morphological and biochemical alterations induced by FasL were
similar in wild-type (wt) and Cav-null mouse lung fibroblasts, the time course and the
extent of the alterations were greater in the Cav-null fibroblasts. Several salient features
of Cav-null fibroblasts response such as loss of membrane potential, fragmentation
of the mitochondrial continuum concurrent with caspase-8 activation, and subsequent
Bid cleavage, prior to caspase-3 activation were detected. Furthermore, M30 antigen
formation, phosphatidylserine expression and DNA fragmentation were caspase-3
dependent. SiRNA-mediated silencing of XIAP and c-FLIP, individually or combined,
enhanced the sensitivity of lung fibroblasts to FasL-induced apoptosis. Pharmacological
inhibition of Bcl-2 had no effect. Together our findings support a mechanism in which
CD95/Fas engagement activates caspase-8, inducing mitochondrial apoptosis through
Bid cleavage. XIAP and c-FLIP fine tune this process in a cell-type specific manner.
Keywords: caveolin 1 and caveolin 2 knockouts, double-siRNA, Bid, caspase-8, IAPs, lung fibrosis
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF), -is a chronic lung disease-, and the most frequent and
relentless form of interstitial pneumonias (Noble et al., 2012). It manifests over several years and
is characterized by drastic scarring of the lung tissue and an unyielding loss of lung function in
the absence of any known initiating factors (Martinez et al., 2005; King et al., 2011). IPF: (i) is
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a diffuse lung syndrome that belongs to a subgroup of diseases
known as idiopathic interstitial pneumonia (IIP), (ii) has an
unknown etiology and is associated with a pathologic pattern
known as usual interstitial pneumonia (UIP), and (iii) is often
referred to as IPF/UIP (Meltzer andNoble, 2008). Areas of patchy
fibrosis, sub-pleural honeycombing, and fibroblastic foci (Crystal
et al., 2002) composed of a collagenous matrix with embedded
apoptosis-resistant fibroblasts/myofibroblasts (Selman et al.,
2001) represent the histological blueprint of IPF.
Current evidence emphasizes the important role of apoptosis
in normal lung homeostasis and in pathogenesis of a variety
of lung diseases (Chin et al., 1998; Uhal, 2002; Demedts et al.,
2006; Kuwano, 2007). Lung cells apoptosis occurs through a
highly regulated proteolytic process that eliminates unwanted,
damaged, or altered cells. Depending on the cell type and local
cues, apoptosis could have helpful or harmful effects. It has
been suggested that, apoptosis in different cellular populations
is involved in the pathogenesis of IPF and the presence
of unresolved IPF lesions. However, its precise role is not
well-established. Understanding the factors that mediate cell-
specific survival and death, becomes of paramount importance
for deciphering the initiation, propagation and prognosis
of IPF.
Apoptosis of the lung epithelium has been suggested to alter
of the integrity of the alveolo-capillary basement membrane, a
stage recognized as a point of “no return” for the fibrotic process
(Wallace et al., 2007). This alteration assists the epithelial-to-
mesenchymal transition of some lung cells (Tanjore et al., 2009),
while failure of the re-epithelilization and re-endothelialization
processes leads to the destruction of the lung architecture
(Keeley et al., 2010), and the emergence of apoptosis-resistant
myofibroblasts (Hecker et al., 2011; Hecker and Thannickal,
2014). In IPF the emerging myofibroblasts play important roles
in tissue remodeling and fibrogenesis. Some myofibroblasts
not only acquire characteristics of apoptosis-resistance but also
display enhanced production of extracellular matrix components
and cytokines (Chilosi et al., 2006; Kuwano, 2007; Jin and
Dong, 2011; Hinz et al., 2012; Hu and Phan, 2013). It has
been shown that when these modified cells are located in
the fibro-proliferative areas, they display continuous activation
of several signaling pathways that promote cell survival, such
as the PI3K/AKT pathway (Fattman, 2008). Moreover, several
mechanisms have been proposed to account for the apoptosis-
resistance of fibroblasts, including: (i) upregulation of the
WNT5A gene that triggers fibroblast proliferation and inhibits
apoptosis through a non-canonical WNT/β-catenin pathway
(Vuga et al., 2009), (ii) diminished prostaglandin E2 production
caused by persistent activation of the pro-survival kinase
Akt (Maher et al., 2010), (iii) cytokine-mediated pathways
such as, activated TGFβ1 overexpression via the inhibition
of plasminogen activation (Horowitz et al., 2008) along with
inducible nitric oxide synthase activation (Zhang and Phan,
1999) and (iv) increased endothelin-1 levels via pro-survival
PI3/AKT signaling (Swigris and Brown, 2010). Interestingly, low
expression of cell surface FasL, vs. high levels of the apoptosis-
inhibiting soluble Fas (sFas) has also been related to fibro-
proliferation (Buhling et al., 2005). CD95/Fas, a death receptor
of the tumor necrosis factor receptor (TNF-R) superfamily, has
been implicated in the development of IPF owing to its ability
to promote lung injury via apoptosis of alveolar epithelial cells
(Hagimoto et al., 1997). Previous studies have shown that alveolar
epithelial cells, fibroblasts, and myofibroblasts express CD95 in
vitro, as well as in the fibrotic lung tissues of IPF patients
(Kazufumi et al., 1997; Kuwano et al., 1999; Kuwano, 2007).
These findings suggest a potential dual role of CD95 function.
CD95 initiate epithelial apoptosis and, facilitate myofibroblasts
apoptosis and clearance during the resolution phase of lung
injury (Kuwano, 2007; Cha et al., 2010; Golan-Gerstl et al.,
2012). The molecular events that are activated by FasL to
trigger apoptosis are well-characterized (Strasser et al., 2009). The
events begin with the activation of caspase-8, which after leaving
the death-induced signaling complex (DISC), targets specific
substrates within the cytosol, i.e., the effector caspases-3, caspase-
7, and the pro-apoptotic BH3 interacting-domain death agonist
protein (Bid), that are critical for CD95-mediated apoptosis
(Luo et al., 1998; Stennicke et al., 1998; Kuwano, 2007). In this
pathway, the levels of CD95 on the cell surface determine the
extent of effector caspases activation as well as the efficiency
of both; the assembly of the DISC and proteolytic activation
of Bid; whereas the levels of inhibitors of these processes, such
as the inhibitors of apoptotic proteins (IAPs), –particularly the
X-linked inhibitor of apoptosis protein (XIAP) and FADD-like
interleukin-1b-converting enzyme (FLICE) inhibitory proteins
(c-FLlP; Kaufmann et al., 2012), restrict their activation.
Significantly, the recent availability of caveolin-1 (Cav1−/−),
and caveolin-2 (Cav2−/−) deficient mice revealed a main
phenotype of generalized fibrosis (Drab et al., 2001; Razani et al.,
2001, 2002).
Caveolin-1 (cav1) has been associated with the regulation of
cell signaling and endocytosis in a plethora of cell types. Yet,
its association with the fibrosis remains largely uncharacterized
despite the evidence that the protein has inhibitory effects
on matrix proteins production and the caveolin gene was
demonstrated, by knockout, to function primarily as an
antifibrotic gene (Gvaramia et al., 2013). However, the Cav-
null mice are not yet well-characterized and comparisons of
these mice to human disease are limited (Tourkina et al., 2005,
2008; Wang et al., 2006; Kim et al., 2008). Emerging data
demonstrates that in the lung tissue and fibroblasts of IPF
patients, there is a reduction of Cav-1 expression relative to
the control samples (Wang et al., 2006); as well as in the lung
tissues of patients with skin scleroderma (Del Galdo et al., 2008;
Tourkina et al., 2008; Gvaramia et al., 2013). An accumulated
body of evidence indicates the presence of low levels of cav1
in human IPF, and demonstrates that cav1 is an antifibrogenic
molecule. Nevertheless, one of the main functions of the cav1
chaperone–for cav2 exit to the Golgi apparatus has not, also, been
considered. We recently reported that: (i) Cav2−/− mice, with
normal levels of cav1, develop lung fibrosis over time and (ii)
cav2, not cav1 drives the fibrotic process (Predescu et al., 2011,
2012).
Based on these findings, we aimed to investigate the apoptotic
cellular changes and the main molecular mechanisms involved
in the response of lung fibroblasts isolated from Cav1−/− to
Cav 2−/− mice to apoptosis inducer FasL. We investigated
the molecular mechanisms and cellular manifestations used
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by the cav null fibroblast to attain apoptosis-resistance, by
comparing them to fibroblasts from wt mice and with two other
lung cell types. We analyzed the sequential morphological and
biochemical changes of the apoptosis-resistant fibroblasts, and
determined the role of IAPs and c-FLlP in their susceptibility to
FasL- induced apoptosis.
MATERIALS AND METHODS
Materials
All tissue culture reagents were from Lonza (Walkersville, PA)
and their detailed description is specified in Supplementary Data.
All EM reagents and the polylysine coated glass cover slips
were from EM Science (Hatfield, PA), while the JEOL JEM-
1220 transmission electron microscope fitted with a Gatan digital
camera, and the JEOL JSM-6320F high resolution Field Emission
scanning electron microscope, from electron microscopy facility
of University of Illinois at Chicago, were used for taking pictures.
All chemicals and reagents for electrophoresis along with the
antibodies (Abs) used and different kits used are listed in
Supplementary Data.
Animals
Cav1−/−, strain Cav1tm1Mls/J, and the control mice, strain
B6129SF2/J, hereafter referred as wild type (wt) mice, were
obtained from Jackson laboratory, while Cav2−/−, on the
same background as the wt-mice were provided by Professor
Michael Lisanti. The Cav2−/− mice were genotyped every 3–
6 months and breed to form a small Cav2-null colony. Mice
were housed under standardized pathogen-free conditions in
the Rush University animal facility. All experimental procedures
involving mice were performed under direct supervision of
Rush Institutional Animal Care and Use Committee and the
surgical procedures executed under anesthesia as detailed in
Supplementary Data. All efforts weremade tominimize suffering;
in addition all mouse studies adhered to APS’s Guiding Principles
in the Care and Use of Vertebrate Animals in Research and
Training and were performed according with the IACUC
approved protocol number 14-023.
Cell Isolation, Culture, Treatment, and
Fractionation
Lung fibroblasts from wt-, Cav 1−/− and Cav 2−/− mice were
derived as previously described in Baglole et al. (2005).
One day post-confluent fibroblast cultures were exposed
to different treatments as follows: (i) for apoptosis induction
detailed conditions are given in the following entry; (ii) for
XIAP activity inhibition the specific inhibitors ABT-199 or ABT-
236 (dissolved in dimethyl sulfoxide as 1,000-fold concentrated
stock) were used at a final concentration of 1 µm; (iii) for
cellular fractionation, confluent culture were treated with Fas
L for different time points, as specified in the figure legends,
or were untreated (controls–c) and then a cytosolic and a
membrane fraction were prepared by differential centrifugation
as in Predescu et al. (2001).
Isolation and characterization of murine lung endothelial
cells (ECs) was done as in Predescu et al. (2013) while murine
epithelial cells (EpCs) were isolated as in Blickwede and Borlak
(2005); the cells were used between passages 4–6. An extended
description of cell isolation, characterization and culture is given
in Supplementary Data.
Induction of Apoptosis
All experiments were performed on quiescent fibroblasts (grown
in DMEM + 0.1% FCS for 24 h). Preliminary experiments
carried out with different concentrations of FasL (5, 10, 30,
60, 90, 100 µg/mL) and CHM (10, 20, 40, 60, 90, 100, 120
µg/mL) allowed us to establish the cellular threshold–90 µg/mL
FasL in the presence of 100 µg/mL CHM–needed for apoptosis
induction, this condition will be referred through the paper as
FasL-induced apoptosis. Additionally, isolated fibroblasts were
treated for different time points (1, 2, 4, 8, 12, 24, and 48 h); and
also we changed the succession of FasL and CHM administration
in order to establish the best conditions for apoptosis induction.
siRNA Studies
For single transfections 2 × 106 cells in a 400 µL volume were
transfected with specific siRNAs and the working conditions
listed in Supplementary Data. For double knockdowns, cells were
plated on 60 cm2 plastic Petri dishes, rested for 24 h and the
firs transfection, using lipofectamine, was performed as above.
The second Silencer Select siRNA was then transfected using
lipofectamine as described in Predescu et al. (2013) and as
described in Supplementary Data.
Cellular Proliferation Assay on Monomeric
and Polymeric Collagen
Lung fibroblasts isolated from mice were serum-starved for 24
h and placed on monomeric collagen (MC; 200 µg/mL), or on
polymeric collagen (PC; 2 mg/mL) in DMEM+ 10% FCS. Plates
covered with two-dimensional matrices (MC) were obtained as
in Xia et al. (2008) while polymeric matrices (PC) were prepared
as in Tian et al. (2002). Cells (103 cells/well) were grown for 48 h
and then the MTT assay for cellular proliferation was performed
as in Patel et al. (2012). The outcomes were read at 570 nm using
an Epoch plate reader and the results are expressed as number of
cells/mL.
Measurement of CD95, Fas Bound to the
Cell Surface and Secreted into Cell Culture
Media
Expression level of FasL mRNA was analyzed by RT- PCR
using the primers and the conditions detailed in Supplementary
Data. The relative amounts of membrane cell-bound FasL were
measured by western blotting (WB), of membrane fraction
obtained by cell fractionation as described under cell culture and
the details given in Supplementary Data. The Fas secreted into the
culture media (sFas) was measured with the MFL00 kit according
to the instructions, while the CD95 expressed in the membranes
of isolated cells was detected by cell surface ELISA using the same
Ab utilized for immunostaining.
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AnnexinV Staining
Phosphatidyl serine (PS) expression on the outer leaflet of
plasmalemma proper was monitored by staining with AnnexinV
while propidium iodide was used to identify the necrotic
cells. Only the adherent cells were evaluated by fluorescence
microscopy using appropriate filters. Methodological details are
given in Supplementary Data.
TUNEL and Cellular DNA Fragmentation
Permeabilized cells exposed to TUNEL mixture, were processed
as per manufacturer protocol, and examined with a Zeiss
Axioimager M1 fluorescence microscope as detailed in
Supplementary Data.
Caspase Activation
The presence of caspase-2, -3, -6, -8, and -9 activity in FasL +
CHM treated fibroblasts was determined using 5× 106 cells (wt-,
Cav1−/−, Cav2−/−) per sample and the protocol recommended
by the manufacturer of KHZ1001-kit. All experiments were
performed in triplicates and the fold-increase in caspase-2,
-3, -6, -8, and -9 activities was determined by comparison to
non-treated controls. After having established the presence of
mentioned caspases we used 2 × 107cells for every type of
fibroblasts stimulated with FasL to measure the increase in
specific enzymatic activities of caspase-3, -8, -9, at 24 h and
48 h, using the protocols provided by the corresponding kits,
and a thorough description of the method(s) is reported in
Supplementary Data.
Mitochondrial Function
The mitochondrial transmembrane potential (19m) was
determined with the JC-1 assay kit as per manufacturer
instructions using a 96 well black plate and 5 × 105 cells as
described in Supplementary Data.
The structural integrity of the mitochondrial continuum
was assessed by transmission electron microscopy (TEM) of
unstimulated and FasL-stimulated fibroblasts, as well as by
determining its DNA copy number after FasL induced apoptosis
of mouse fibroblasts using the method of Miller et al. (2003) and
the conditions detailed in Supplementary Data.
Keratin 18 Fragmentation Assay
The specific proteolytic cleavage of Keratin 18 (K18) is an event-
taking place before disruption of membrane asymmetry and
breakage of DNA strands. K18 as a type I intermediate filament
protein and one of the major component of epithelial cells, is
cleaved by activated caspases, exposing a neo-epitope (M30) that
is specifically recognized by M30 CytoDEATHTM monoclonal
Ab, which detects only apoptotic cells (not viable or necrotic
cells). Consequently, the usage of M30 CytoDEATHTM Ab as
a unique tool for easy and reliable determination of apoptosis
from very early until well-advanced stages was rationalized to
specifically recognize single cells and on tissue sections only cells
undergoing apoptosis. However, accumulating data suggests its
presence in humanmyofibroblasts in the late stages of pulmonary
fibrosis (Moodley et al., 2004; Larsson, 2008; Ley et al., 2011),
and therefore we have used it for immunostaining of isolated
fibroblasts from wt, Cav1−/− and Cav2 −/−.
Western Blotting and Immunofluorescence
Usually 20–80 µg total proteins per lane were separated on a
SDS-PAGE minigel and transferred to nitrocellulose membranes
(NC) as in Towbin et al. (1979). Strips of NC were incubated with
the primary Abs and processed as in Predescu et al. (2005). The
detailed conditions forWB as well as for immunofluorescence are
given in Supplementary Data.
Transmission Electron Microscopy (TEM)
and Scanning Electron Microscopy (SEM)
For TEM, Wt-, Cav 1−/− and Cav 2−/− fibroblasts were grown
in 35 mm plastic Petri dishes until 70–80% confluent, exposed to
FasL, then at predetermined time point, the media was removed
and the adherent cells were prepared for flat embedding as
in Predescu et al. (2003), while SEM examination of cultured
fibroblasts was performed as in Knezevic et al. (2009) and in both
cases details are provided in Supplementary Data.
Statistical Analysis
All experiments were conducted a minimum of three times.
Statistical analysis using SPSS version 17.0 software were
performed by one-way ANOVA for pair-wise multiple
comparisons, while comparisons among groups were performed
with a Neuwman-Keul multiple comparison test; p < 0.05 was
considered significant.
RESULTS
Characterization of Murine Lung
Fibroblasts Isolated from Cav1−/− and
Cav2−/− Mice
Lung tissue from Cav1−/−, Cav2−/−, and wt-mice (C57B strain)
was used to isolate fibroblasts that were later characterized
morphologically by immunostaining for the expression of prolyl-
4-hydroxylase and α-SMA. The anti-prolyl-4-hydroxylase Ab
detected the presence of the enzyme in all three types of
fibroblasts (Figure 1A). The immunoreactivity for α-SMA varied
among the isolated fibroblasts (Figure 1B). Five regions of
interest (ROIs) chosen randomly from -three coverslips of
each fibroblast type, indicated that the percentage of α-SMA
positive cells was 4 ± 0.2%, p < 0.05, in wt-fibroblasts; 33
± 6%, p < 0.05 in Cav1−/− fibroblasts and 39 ± 7%, p <
0.04 in Cav2−/− fibroblasts. Additional immunostaining studies
indicated that the majority of cells, (71% of all the fibroblasts
types), were immunoreactive to Thy-1, an antigen specific to
fibroblasts subtypes. They also expressed a fibroblast specific
antigen recognized by the monoclonal Abs ER-TR7 and stained
positive for vimentin, a marker for the mesenchymal origin
(not shown). Thus, our immunostaining data strongly suggest
that the isolated cells are truly fibroblasts and were used for all
experimental procedures.
At the EM level, as expected, Cav1−/− fibroblasts lacked any
detectable caveolae (Figures 1E,F), while retaining their clathrin-
coated vesicles (Figure 1E, inset). The number and structure
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FIGURE 1 | Specific morphological and proliferative features of isolated mouse lung fibroblasts. Immunofluorescent staining of fibroblasts isolated from 2
months old mice (1 day after confluence) for the prolyl-4-hydroxilase specific marker reveals its presence in all three types of cells; n = 7. (B) Staining of isolated
fibroblasts (same conditions as in A) with α-SMA Ab showing a higher number of positive cells in Cav1−/− and Cav2−/− phenotype; n = 8. Bars: 30 µm (A); 25 µm
(B). EM morphology of isolated fibroblasts illustrates by sections through the cells outside the nuclear area (C,E,G) and sections through the nuclear area (D,F,H). (C)
Two overlapping wt-fibroblasts display most of regular organelles: Golgi -G-, mitochondria –m-, caveolae (arrows); (D) and a nucleus with an continuous rim of
condensed chromatin; n = 6. (E,F) Cav1−/− fibroblasts show total lack of caveolae, while they do have CCVs (insets) all other subcellular organelles, including
(Continued)
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FIGURE 1 | Continued
mitochondria (m), ER spread throughout the cytosol and the nucleus is filled with relaxed chromatin; n = 6. (G) The Cav2−/− fibroblasts showing a sizable population
of caveolae identical in size, number and cellular distribution with wt-fibroblasts, along with a nucleus crammed with relaxed chromatin (H). Bars: 150 nm (C); 200 nm
(D,F); 350 nm (E); 300 nm (G,H). (I) When isolated fibroblasts were seeded on monomeric collagen-1 (MC) the wt-fibroblasts (blue graph) display a 50% increase in
their proliferation vs. Cav1−/− fibroblasts (red graph) and Cav2−/− fibroblasts (green graph). (J) Cav-null fibroblasts isolated from the lungs of mice at different ages
when plated in polymeric collagen-1 (PC) are more proliferative (>20%) than the corresponding wt-fibroblasts; 0 means 2 weeks of age, while 1, 4, and 9 are months
(m) after birth. n = 12; *p < 0.05 and ‡p < 0.01 between different months. In all conditions (MC and PC) the differences between 1, 4, 9 months, and 2 weeks are
statistically significant p < 0.01. Note also the lack of statistical differences between cav1−/− and cav2 −/− null fibroblasts in both experimental conditions as well as
at different time points.
of vesicular carriers between wt- and Cav2−/− fibroblasts did
not differ (Figure 1C vs. Figure 1G). Morphometric analysis
(57 electron micrographs of each type of fibroblasts) of the
caveolar numbers per cellular profile revealed 0.5 ± 0.3 caveolae
in the Cav1−/− fibroblasts (p < 0.001); 17.6 ± 3.4 caveolae
in the wt-fibroblasts (p < 0.003) and 18.2 ± 4.1 caveolae in
Cav2−/− fibroblasts (p < 0.002). Using the Neuwman-Keul test
we did not found any statistical difference between the number
of caveolae in wt vs. Cav2−/− fibroblasts (p < 0.27). At this
level of resolution, the fibroblasts isolated from the wt- and both
Cav-null mice exhibited similar morphological features: (i) a rich
endoplasmic reticulum (ER), (ii) a full-bodied Golgi apparatus
(G, Figure 1C), (iii) several mitochondria scattered throughout
the cytoplasm (m, Figures 1C,E) and (iv) a sizeable smooth
nucleus (Figures 1D,F,H). This set of data correlated with the FM
staining give us the confidence that the isolated cells are indeed
fibroblasts and therefore worthy for the experimental procedures.
The proliferative potential of lung fibroblasts isolated
from mice of different ages was examined in both 2D and
polymeric collagen-1 matrices in conjunction with the MTT
assay, as described in the Section Materials and Methods.
Fibroblasts isolated from Cav1−/− and Cav2−/− mice were
50% less proliferative than the fibroblasts isolated from
wt-mice when cultivated on 2D matrices (Figure 1I), but
they were approximately 20% more proliferative than wt-
fibroblasts when cultivated on polymeric collagen matrices
(Figure 1J). These results are consistent with previous
reports showing that fibroblasts from IPF patients were less
proliferative when cultured on 2D matrices (Ramos et al.,
2001) or, more proliferative on polymerized collagen as
a result of improved integrin signaling (Xia et al., 2008).
Thus, our isolated murine lung fibroblasts are endowed
with morphological and functional features of the fibroblast
phenotype and therefore they are commendable for detection of
structural, biochemical and functional changes induced by FasL
treatment.
Together, these findings demonstrate that the fibroblasts
isolated from Cav-null mice exhibited a characteristic fibroblast
phenotype, with proliferative properties, that can be used
to identify the molecular determinants involved in the
apoptotic-resistance of fibroblasts in IPF. These cells were
used throughout the whole work and referred as isolated
fibroblasts. First the isolated fibroblasts were used to establish
reproducible conditions of apoptosis induction and the
main morphological transformations when treated with
FasL.
Cav-Null Fibroblasts Are
Apoptosis-Resistant: Morphological
Evidence
Preliminary experiments performed with FasL-treated
fibroblasts indicated that apoptosis was not induced even
with concentrations as high as 2 mg/mL. Apoptosis was not
detected when fibroblasts were exposed to 100 µg/mL of the
protein synthesis inhibitor CHM alone (Figure 2A). However,
apoptotic events were induced in all of the fibroblast types
isolated when 100 µg/mL of CHM, followed by 90 µg/mL of
FasL were used (Figure 2A). The data in Figure 2A besides
establishing the conditions of a reproducible method of FasL-
induced apoptosis in isolated mouse lung fibroblasts, also
illustrates that the Cav-null fibroblasts were significantly less
apoptotic than the wt-fibroblasts. Yet, between Cav1−/− and
Cav2−/− fibroblasts no significant differences were determined.
In addition, the same CHM + FasL treatment was required
to induce apoptosis in isolated lung fibroblasts from mice of
different ages (1, 4, and 9 months, not shown). Moreover, the
isolated lung fibroblasts, from 1 month old mice, also became
apoptotic when treated with different concentrations of TNF-α
(1–100 ng/mL). Interestingly, the Cav-null fibroblasts were
more responsive, to TNF-α treatment than the wt-fibroblasts
(Figure 2B). So, we have established that the isolated fibroblasts
respond to FasL only in the presence of CHM and these
conditions were utilized throughout our work as Fas-induced
apoptosis.
Next, we investigated the detailed morphological changes
activated by FasL-induced apoptosis using TEM and SEM.
Employing 95% confluent cell cultures and a flat embedding
method to prepare the isolated fibroblasts for TEM, we noticed
that all three types of fibroblasts underwent cell shrinkage as early
as 15min after FasL treatment that reached its maximum after 1 h
(Table 1). During this time interval, the cells began to retract and
showed an increased number of filopodia (Figures 2Cc1–c3,c5,
long arrows). Morphometric surveys on 150 full cellular profiles,
for every type of isolated fibroblast, estimated a total of 349 ± 31
filopodia, (p < 0.001) in wt, 351 ± 42, (p < 0.002) in Cav1−/−
fibroblasts and 351 ± 44, (p < 0.001) in Cav2−/− fibroblasts;
each of these values are given per µm of cellular perimeter. The
following values indicate the number of filopodia per cellular
profile: 72 ± 12, (p < 0.001) in the wt-fibroblasts, 105 ± 19,
(p < 0.002) in the Cav1−/− fibroblasts, and 110 ± 26, (p <
0.001) in the Cav2−/− fibroblasts. Furthermore, the density of
filopodial extensions (the number of filopodia/length of cellular
perimeter [#/µm length]) was 0.21 in the wt-fibroblasts, 0.30
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FIGURE 2 | Apoptotic-resistance characteristics of wt- and Cav-null fibroblasts. (A) Mouse fibroblasts (wt-, Cav1−/−, and Cav2−/−) exposed, for 24 h, to
either 90 µg/mL FasL or 100 µg/mL CHM are resistant to apoptosis; combined FasL + CHM treatment induces their apoptotic death; n = 8, *p < 0.01 vs. control
(Continued)
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FIGURE 2 | Continued
(untreated fibroblasts) and ‡p < 0.05 vs. FasL or CHM alone. The differences between FasL and CHM treated fibroblast did not reach statistical significance, p <
0.24, n = 8. (B) TNF-α treatment (2 h) induces apoptosis in all fibroblasts in a concentration dependent manner. n = 5; *p < 0.001, ‡p < 0.05. (C) By TEM [4 h post
FasL (c1, c2, c3) and 2 h (c4, c5, c6)] all fibroblasts show filopodial extension (c1, c2, c3, c5, arrows), display myelinic bodies (c1, c2, arrowheads), show increase in
the number of mitochondrial units [c4 (m), c6 (circled area)], along with enlarged ER (c4, c6, arrows) and display increased number of cytoplasmic vacuoles (v; c2, c5,
c8). Representative electron micrographs demonstrate the nuclear condensation in all three types of fibroblasts (c7–c9) and no differences in dismantling of cellular
nuclei (c6, c7, c8, c9); Bars: 250 nm (c1–c9); n = 6. (D) Scanning EM (8 h post-FasL treatment of fibroblasts isolated from 2 months old mice) reveals the extent of
cellular blebbing and the abundance of filopodial projections in mouse fibroblasts after FasL-treatment. Bars: 25 µm; n = 8.
TABLE 1 | The onset of morphological apoptotic alterations of mouse lung fibroblasts induced by FasL + CHM.
Morphology Wt-fibroblasts Cav1−/− fibroblasts Cav 2−/− fibroblasts
1 h 2 h 6 h 24 h 1 h 2 h 6 h 24 h 1 h 2 h 6 h 24 h
CELL SURFACE
Shrinkage +++ +++ +++
Retraction +++ +++ +++
Filopodia ++ + + ++ + + ++ +++ ± + ++ +++
Blebbing ± + ++ +++ + + ++ ± + + ++
CYTOPLASM
Myelinoid bodies + + ++ ± + + + ± + ++ + +
Enlarged ER + ++ ++ + + +++ + ++ ++
NUCLEUS
Condensation + ++ +++ ± + ++ ± + +++
+, <40% of cells; ++, <50% of cells; +++, >60%; ±, inconsistent presence.
in the Cav1−/− fibroblasts and 0.33 in the Cav2−/− fibroblasts
indicating that these cellular nanoprotrusions are 1.5-times
more numerous in the Cav-null fibroblasts relative to the wt-
fibroblasts.
Other evident morphological changes encountered were
membrane blebbing, the emergence of myelinic bodies and
the development of cytoplasmic vacuoles; all are traits of
apoptotic cells. We detected myelinic bodies as early as 30
min after-FasL treatment that apparently, disappeared after 6
h (Figures 2Cc1,c2, arrowheads, Table 1), and a large increase
in the number of cytoplasmic vacuoles, after FasL treatment,
beginning at 2 h (Figures 2Cc2,c5, Table 1) and lasting more
than 24 h (Figure 2Cc8, Table 1). The ER remained intact;
however 2 h after FasL treatment became dilated in each of
the isolated fibroblast types (Figures 2Cc4–c6, short arrows;
Table 1). Assessment of the nuclear morphology revealed that
2 h after FasL exposure, the nuclear chromatin became more
condensed (Figures 2Cc6–c9 and Table 1), followed by cell
nucleus compaction (size reduction determined by a decrease
in circumference and surface area) at later time points. After
only 24 h of Fas treatment all of the morphological changes
ended in karyorrhexis. Furthermore, SEM analyses of the
FasL-treated fibroblasts indicated that between 2 and 6 h
post treatment, the fibroblasts shed blebs, which were more
numerous in the wt-fibroblasts than in the Cav-null fibroblasts
(Figure 2D). Morphometric analysis of the bleb distribution
per cellular profiles, performed on 155 wt-fibroblasts, 237
Cav1−/− fibroblasts and 251 Cav2−/− fibroblasts, 48 h post-
FasL treatment, indicated 44 ± 17 blebs/µm2 of cellular surface,
(p < 0.002) in the wt-fibroblasts, only 23 ± 9 blebs/µm2 of
cellular surface, (p < 0.004) in the Cav1−/− fibroblasts and
27 ± 6 blebs/µm2 of cellular surface, (p < 0.001) in the
Cav2−/− fibroblasts. Together, these observations suggest that
the fibroblasts isolated from Cav-null mouse lungs have an
apoptosis-resistant phenotype. Data collected, after our extensive
morphological surveys performed on isolated fibroblasts treated
with FasL, give us the needed confidence to use these cells
for widespread biochemical and molecular analyses in order
to unravel the mechanisms and main players behind our
morphological findings.
FasL-Induced Fibroblasts Apoptosis is
Caspase-Dependent
Because DNA cleavage into oligonucleotides fragments is
a key apoptotic biochemical step, we investigated DNA
fragmentation in fibroblasts using the TUNEL assay and
microscopic evaluation, 48 h after FasL exposure (Figure 3A).
Morphometric analyses performed on 95 ROIs indicated on
average, 34 ± 8 TUNEL-positive cells in the wt-fibroblasts, (p <
0.003), 21 ± 9 TUNEL-positive cells in the Cav1−/−fibroblasts,
(p < 0.001) and 22 ± 7 TUNEL-positive cells in the
Cav2−/−fibroblasts, (p < 0.002; Figure 3B). In addition, the
percentage of apoptotic cells was always lower in the Cav-null
fibroblasts when compared to the wt-fibroblasts. The number
of TUNEL positive Cav1−/− fibroblasts was 37% lower and
the number of TUNEL positive Cav2−/− fibroblasts was 34%
lower than that of TUNEL-positive wt-fibroblasts. Interestingly,
in the wt- and Cav2−/− fibroblasts, the TUNEL-positive cells
were evident 4 h after FasL exposure, while in the Cav1−/−
fibroblasts they were apparent after 2 h. An increasing trend
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FIGURE 3 | FasL-induced apoptosis of mouse fibroblasts is caspases-dependent. (A) The upper panels illustrate the TUNEL staining of mouse fibroblasts at
48 h post- FasL treatment; while the lower panels illustrate the DAPI staining for the detection of cellular nuclei. Bar: 30 mm, n = 7. (B) Morphometric analyses of
TUNEL-positive fibroblasts at different time points after FasL exposure. Note that at 48 h after FasL, the progression of apoptosis is inhibited by 30 µ of pan caspases
inhibitor MZ-VAD-FMK (CI); n = 4 for every time point and type of fibroblasts, *p < 0.05 when wt-fibroblasts are contrasted with Cav-null fibroblasts. (C) Caspase-8
specific activity shows statistical differences between wt- and Cav-null fibroblasts (*p < 0.05), and no significant differences between Cav-null fibroblasts, †p < 0.26;
n = 6 for each type of fibroblasts. (D) Caspase-3 activity was higher in wt-fibroblasts when compared with cav null fibroblasts, *p < 0.05. Its activity was slightly higher
in Cav1−/− compared to Cav2−/− fibroblasts, but without statistical significance, †p < 0.14; n = 6 for each type of fibroblasts. (E) The higher activity of Caspase-9 in
the first 24 h reached statistical significance for wt-fibroblasts when compared to Cav1−/− fibroblasts, *p < 0.05, but not when compared with Cav2−/− fibroblasts;
p < 0.1; its activity was not different between Cav1−/− and Cav2 −/− fibroblasts, †p < 0.22. n = 9 for each type of fibroblasts. (F) Activation of Caspase-8 (top
panels) was evident by 2 h in all types of fibroblasts, peaked between 6 and 12 h post treatments and remained evident in cav null fibroblasts even beyond 24 h, while
its total amounts didn’t change over time. (G) Activation of Caspase 3 (top panels) was delayed, but evident by 4 h and persisted for 48 h. The data from F and G are
representative for three experiments for every time point, repeated three times.
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of apoptotic cells over time was observed in the wt-fibroblasts.
Increases in apoptotic Cav-null fibroblasts, were not prominent,
and no statistical significance (p < 0.4) was reached between
Cav1−/− and Cav-2−/− fibroblasts (Figure 3B). In each of the
isolated fibroblast types, the treatment with the specific caspase
inhibitor Z-VAD-FMK (30 µM) inhibited DNA fragmentation
(Figure 3B). Given this result, we investigated the involvement
of caspases in FasL-induced fibroblast apoptosis. First, we
investigated the expression of relevant caspases in the isolated
fibroblasts, endothelial and epithelial cells by WB of cell
lysates. Detection of caspase-2, caspase-3, caspase-6, caspase-7
caspase-8, and caspase-9 in each of the cell types (Figure S1A,
Supplementary Data), revealed that the expression of caspase-
3 and caspase-8 were always higher in the isolate fibroblasts
when compared to the endothelial and epithelial cells (red boxes
from Figure S1A, Supplementary Data), and slightly higher in
the caveolin null fibroblasts relative to the wt- fibroblasts (Figure
S1B, Supplementary Data). As illustrated in panel B from Figure
S1 significant differences (p < 0.003) were noticed only between
isolated fibroblasts and the other two cell types. Next, using the
Caspase Colorimetric Protease Assay we discovered that after
FasL treatment the caspase-3, caspase-8, and to a lesser extent
caspase-9 were activated in all the fibroblast types (Figure S2,
Supplementary Data). The FasL-induced activation of caspase-
3 and caspase-8 was higher in the Cav-null fibroblasts (p <
0.05), while the activation of caspase-9 did not differ significantly
between the wt and Cav-null fibroblasts (p < 0.33). This most
likely reflects the different levels of caspase expression illustrated
in Figure S1A, Supplementary Data. To resolve this discrepancy
we determined the specific activity of the three activated caspases
(3, 8, and 9).
Assessment of the specific enzymatic activity of the
different caspases after-FasL treatment, revealed that caspase-8
(Figure 3C) was activated first in all of the isolated fibroblasts,
persisted for 24 h and its activity was less than half at 48
h. Preliminary experiments (not shown) indicated that high
caspase-8 activity could be detected in the first 10 sec, reaches
near maximal values at 10 min after FasL stimulation and
then its activation profile is shown in Figure 3C. Caspase-3
was activated usually in the wt-fibroblasts (Figure 3D) more
than in Cav-null fibroblasts, lasted 24 h, and retained more
than 50% of activity at 48 h. Caspase-9 activation was lower
(Figure 3E), peaked at 24 h but remained active more than 48 h
when compared to caspase-8 and caspase-3. It became obvious
that: (i) the activation of caspase-8 is rapid and sustained,
up to 48 h after stimulation, (ii) the activation of caspase-3
is more robust (>1.5 orders of magnitude greater than the
other two caspases), but not as prolonged (up to 24 h), (iii) the
activation of caspase-8 and caspase-9 was observed mainly in
the Cav-null fibroblasts and (iv) the activity of all three caspases
was inhibited by the specific peptides [(SP), Figures 3C,D,E].
Because caspase-8 is the initiating protease and caspase-3 is
the executing protease, we investigated their activation using
WB. The appearance of the cleavage fragments of caspase-8
(Figure 3F) and caspase-3 (Figure 3G) in the cell lysates of
isolated fibroblasts, followed the same activation time course
detected by measuring their specific activity. The presence of
fast activated caspase-8 in isolated fibroblast usually reflects
an activation of the mitochondrial pathway and therefore we
investigated the status of the mitochondrial continuum from
isolated fibroblasts.
Fibroblasts’ Mitochondria Participate in
Fasl-Induced Apoptosis
Another organelle affected by FasL exposure in the isolated
fibroblasts, was the mitochondrion. EM analyses of the
fibroblasts, 1 h after FasL exposure, frequently revealed elongated
and condensed mitochondrial profiles along with increased
cellular density (Figure 4). In fact, the EM surveys indicated that
the earliest detectable morphological event that occurred after-
FasL exposure was the appearance of a fragmentedmitochondrial
continuum followed by cells shrinkage. These two events began
after 15 min and became well-defined by 30 min. To better define
the mitochondrial alterations, we then measured its membrane
potential (19m) using the JC-1 assay kit and the ratio of
the fluorescence intensity. J-aggregates/monomers were used to
calculate changes in 19m as induced by apoptotic treatment.
We found that 19m was lost within the first hour after FasL
exposure (Figure 4D). Thus, all studies were performed within
1 h of FasL exposure. Since the EM morphological surveys,
of the cells exposed to FasL, suggested an increased number
of mitochondrial profiles per cell, we determined whether the
number of mitochondrial DNA copies /cell changed after the
induction of apoptosis. The presence of the mitochondrial
transcription factor (mtTFA), a key regulator of mtDNA
replication, with a level that is proportional to mtDNA (Choi
et al., 2001), was investigated using qPCR with 4 ng of each total
cellular DNA and linearized pGEMTE-12S vector. A logarithmic
regression of the standard sample was used to determine the
number of mtDNA copies per pg of total cellular DNA (Table 2).
The average number of mtDNA copies per cell (Table 2) was
863 in the wt-fibroblasts, 889 in the Cav1−/− fibroblasts and the
883 in the Cav2−/− fibroblasts. The FasL-treated and untreated
fibroblasts did not differ significantly (p = 0.4 in wt-, 0.23
in Cav1−/− lines 32 and 0.37 in Cav2−/− fibroblasts). There
were no differences between different types of fibroblasts. Our
findings indicate that the total amount of mtDNA/cell and/or
the mtDNA/total cellular DNA ratio do not change after FasL-
induced apoptosis in any type of the fibroblast types (Table 2).
Therefore, the status of the mitochondrial continuum and not
the number of mitochondria was affected. Similar increases were
observed in the apparent density of mitochondrial units along
with the loss of its membrane potential during the first hour
after FasL in fibroblasts isolated from mice of different ages
(not shown). Hence, we concluded that after FasL treatment,
the mitochondrial mass/cell does not change and there is
more isolated mitochondrial units/cell, due to the widespread
fragmentation of the mitochondrial continuum. Fast activation
of the initiator protease- caspase-8- (s to 10 min), followed by the
fragmentation of mitochondrial continuum starting 10–15 min
after FasL stimulation, is a certain sign that the mitochondrial
pathway take part in isolated fibroblasts response to CD95
apoptosis signaling.
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FIGURE 4 | Fibroblasts mitochondria participate in FasL-induced apoptosis. Representative electron micrographs of the mouse wt-fibroblasts (A, a1),
Cav1−/− fibroblasts (B, b1) and Cav2−/− fibroblasts (C, c1) demonstrate the increased number of small mitochondrial units scattered all over the cytoplasm after
FasL treatment; Bars: 350 nm (A–C); 500 nm (a1,b1,c1); n = 6 for each type of fibroblasts. (D) Adherent fibroblasts, treated with FasL and CHM (24 h) and then
incubated with JC-1 staining solution shows that untreated (U) cells have lots of J-aggregates, and that there are less J-aggregates and more monomeric JC-1 after
FasL treatment, indicative of an altered 19m. Statistical significant differences (*p < 0.05) were found between FasL-treated and untreated fibroblasts, but when
differences between groups were determined they did not reach statistical significance (p < 0.47); n = 6 for each condition and each type of fibroblasts.
TABLE 2 | Mitochondrial DNA in cultured murine fibroblasts.
Cells wtF Cav1−/− fibroblasts Cav2−/− fibroblasts
−FasL +FasL −FasL +FasL −FasL +FasL
Total DNA mass* (pg/cell) 8.1 ± 1.8 (n = 6) 9.4 ± 0.87 (n = 5) 9.4 ± 1.1 (n = 5) 10.4 ± 0.8 (n = 7) 9.83 ± 1.1 (n = 6) 10.5 ± 0.9 (n = 7)
mtDNA- copies (per cell) 844 ± 192 (n = 6) 882 ± 234 (n = 5) 863 ± 191 (n = 5) 915 ± 188 (n = 7) 857 ± 205 (n = 6) 908 ± 155 (n = 7)
*The predicted mass of a diploid mouse genome of 2.8 × 109 base pairs is 3.3 pg/cell.
Phosphatidylserine, M30 and CD95
Alterations Were Similar in the Cav-Null
and wt-Fibroblasts but with Distinct
Temporal Manifestations
The morphological changes occurring on the cell surface of FasL-
treated fibroblasts were investigated by FM for the detection of
Annexin V, M30, and CD95.
Annexin V staining, of FasL-treated fibroblasts, used to
detect the presence of PS revealed full bodied expression after1
h that became evident at 2 h, reaching its maximum at 6
h. Its expression remained elevated for 48 h (Figures 5A,B).
Interestingly, the expression of PS 3–6 h after FasL treatment
coincided with cell membrane blebbing (Table 1). This finding
was in agreement with the weakening of interactions between the
cell membrane and the cytoskeleton. The staining was weaker
Frontiers in Physiology | www.frontiersin.org 11 March 2017 | Volume 8 | Article 128
Predescu et al. Caveolin Driven Resistance to Apoptosis
FIGURE 5 | Phosphatidylserine, M30 and CD95 alterations are similar in cav-null and wt-fibroblasts but with a distinct temporal manifestation. (A)
Representative Annexin V staining of mouse fibroblasts (wt-, Cav1−/−, Cav2−/−, as indicated) demonstrates the presence of PS on the external leaflet of the
(Continued)
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FIGURE 5 | Continued
plasmalemma proper after FasL stimulation; the images are representative for mice fibroblasts isolated at 4 months old. Note the decreased fluorescence displayed by
Cav-null fibroblasts. Bars: 25 µm, n = 7. (B) Quantitative assessment of PS-positive cells on 70 ROIs, collected from six different experiments for every type of
fibroblasts; *p < 0.05 Cav-null vs. wt-fibroblasts, while no statistical differences (‡p < 0.22) were found between Cav1−/− and Cav2−/− fibroblasts; (C)
demonstrative images demonstrating the presence of M30 antigen, at 48 h, after FasL treatment in fibroblasts isolated from 4 months old mice. Bars = 20 µm, n = 6.
(D) Quantification of M30-positive cells on 45 ROI for every type of fibroblast. Analysis of M30 presence did not reach statistical significance between Cav1−/− and
Cav2−/− fibroblasts; ‡p < 0.31, but it was significant when wt-fibroblasts are compared to control (untreated) cells, *p < 0.05; n = 6 for every time point and cell
type. (E) CD95/FasL presence on fibroblasts isolated from 4 months old mice revealed the same pattern of its surface distribution (scattered immunoreactive puncta)
on all types of fibroblasts. Bars: 25 µm, n = 8. (F) Semi-quantitative evaluation (percentage of CD95/FasL immunoreactive cells out of the total number of cells)
performed on 55 ROI, for each type of fibroblasts, over time reveals that the only significant difference was between wt- and cav null fibroblasts (*p < 0.05) and among
the untreated (control) and FasL-treated fibroblasts. (G) WB analysis of Fas bound to the membrane fraction shows fluctuation on the amounts over a 48 h FasL
treatment; n = 4 for every type of fibroblast and time point and the experiments were repeated three times. The graph on (H) shows the quantitative aspect of
membrane bound Fas, and points to the fact that there is no statistical significance between wt and cav-null fibroblasts, p < 0.25 as well as between Cav1−/− and
Cav 2−/− fibroblasts, p < 0.3. (I) qPCR evaluation of mRNA for CD95/FasL showing that Cav-null fibroblasts synthesize more CD95 than wt-, ECs, and EpCs, n = 6,
p < 0.05, while no statistical significance was detected between ECs and EpCs, p < 0.25. (J) ELISA quantification of soluble form of CD95/FasL (released into culture
media) indicating that the fibroblasts secrete more CD95 than the lung ECs and EpCs. n = 8, *p < 0.01 when fibroblasts are compared to ECs and EpCs and ‡p <
0.05 between different types of fibroblasts. (K) Cell surface expression of CD95 as detected by cell ELISA demonstrated its presence at a higher levels in all fibroblasts
than in the ECs and the EpCs, *p < 0.05; the fact that are no significant differences in FasR amounts between ECs and EpCs, ‡p < 0.27 and the finding that the
surface CD95 was less in Cav-null fibroblasts than in the wt-fibroblasts, ‡p < 0.02.
in the wt-fibroblasts compared to Cav-null fibroblasts after FasL
treatment (Figure 5A). Morphometric analyses indicated that
the number of PS-positive cells in the Cav-null fibroblasts was
always 50% lower than in the wt-fibroblasts (Figure 5B). These
findings: a weaker staining in the wt-fibroblasts compared to Cav-
null fibroblasts, but a lower number of PS positive cells in the
Cav-null fibroblasts, after FasL, were indicative of a constitutive
weakening of membrane-cytoskeleton interactions in the Cav-
null phenotype, that seems to be ones of the salient differences
between the wt and Cav-null fibroblasts.
The initial cellular shrinkage and retraction were
accompanied by changes in the cytoskeletal elements as indicated
by M30 Ab staining (Figure 5C) that specifically recognizes the
newly formed caspase-cleaved epitope of cytokeratin-18. The
emergence of the M30 epitope was well-established 1 h after
FasL treatment in all three fibroblast types. The quantification
of M30-positive cells after FasL treatment demonstrated that
the number of M30-positive cells in the Cav-null fibroblasts
there was 40% lower, on average, than in the wt-fibroblasts
(Figure 5D).
Because the expression of Fas/CD95 may play a critical
role in FasL-induced apoptosis, we investigated its cellular
distribution by FM (Figures 5E,F) and WB (Figures 5G,H). For
the presence of sFasL we used PCR and ELISA (Figure 5J). Post-
FasL treatment, FM indicated a strong signal for Fas/CD95 on
the surface of wt-fibroblasts and a much less intense signal on
the surface of Cav-null fibroblasts (Figure 5E). However, the
number of Fas/CD95-positive cells was 35% lower in the Cav-
null phenotype than in wt-fibroblasts (Figure 5F) at different
time points. WB analysis of sCD95 distribution indicated similar
results: (i) increases in membrane-bound sCD95 (Figure 5G),
(ii) 30–35% lower amounts of CD95 in Cav-null fibroblasts
(Figure 5H), (iii) comparable dynamic development of CD95
expression over time revealed by FM (Figures 5G,H), and (iv)
a lower content (pg CD95/cell) of the receptor in Cav-null
fibroblasts (Figure 5K). Unexpectedly, when the mRNA levels of
Fas/CD95 were assessed with PCR (Figure 5I), we found that its
levels were 1.5 times greater in the Cav-null fibroblasts relative
to the wt-fibroblasts, lung ECs and EpCs. Because the increased
levels of CD95/Fas mRNA do not translate into increased surface
expression, we determined the concentration of sFas in the cell
growth media using ELISA. We found an approximately 2.3-
fold increase of sFas in the media from Cav2−/− fibroblasts and
only a 1.4-fold increase in the media from Cav1−/− fibroblasts.
The ECs and EpCs secreted the least amount of sFasL and
displayed lower levels of surface CD95 when compared to
all types of isolated murine lung fibroblasts (Figures 5H,K).
For CD95, a “FADD-only” recruiting receptor that generates
apoptosis signals or triggers non-apoptotic signaling events, the
apoptosis induced signals are demonstrated to be produced only
when the receptor molecules are located in membrane rafts. In
preliminary experiments we did not found, by immunostaining
of isolated fibroblasts, co-localization of CD95 with cav1, cav2,
and clathrin. So, we concluded that in murine lung fibroblasts
CD95 it is localized within membrane rafts and our data are in
agreement with published data in other cell types.
As the quantities of sFasL do not always correlate with
increased apoptosis resistance and since the isolated Cav-null
fibroblasts display the lowest cell surface amounts of CD95
we consider that the FasR receptor in the fibroblasts is not
the main contributor to the apoptosis resistance to FasL
treatment; it function as a trigger whose signaling effects are fine-
tuned by other contributing molecules. So, we investigated the
contribution of other molecules: IAPs, Bcl-2 family members,
DDR1, and cFLICE in order to reveal the necessary molecular
machinery responsible of the recognized fibroblasts apoptosis
resistance.
XIAP Is a Key Component of Fibroblast’
Resistance to Fas-Induced Apoptosis
Because the members of the IAP and Bcl-2 families of apoptotic-
related proteins regulate mitochondrial triggered apoptosis, we
investigated their expression in the cellular lysates of isolated
fibroblasts by comparing them to murine ECs and EpCs
using WB (Figure 6A). The presence of IAPs “the masters of
cellular apoptosis” was examined. We found that the expression
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FIGURE 6 | IAPs involvement in fibroblast resistance to apoptosis. (A) Representative WB using specific Abs for different IAPs protein expression in the mouse
lung cells–ECs, EpCs, wt-, Cav1−/− and Cav2−/− fibroblasts, as indicated; n = 6 for each IAP. (B) The time course and transient nature of siRNA-mediated
knockdown of four BIRCs: NAIP, cIAP1, cIAP-2, and XIAP- in Cav-null fibroblasts; n = 4 for each IAP and Cav-null fibroblasts. The effects of individual knockdown as
indicated–XIAP (C), cIAP1 (D) and cIAP2 (E), n = 4 experiments for every type of fibroblasts and every time point, *p < 0.05 between controls and cav –null
fibroblasts but †p < 0.1 in between Cav1−/− and Cav2−/− fibroblasts. The combined knockdown–XIAP/cIAP1 (F), cIAP1/cIAP2 (G), and XIAP/cIAP1 (H) effects in
fibroblasts resistance to FasL-induced apoptosis; n = 6, *p <0.05 when compared to untreated fibroblasts.
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of NAIP/BIRC1 and c-IAP1/BIRC2 was slightly increased in
fibroblasts (12 and 10%, respectively); while the expression of
IAP2/BIRC3 was 11% lower than in resting Cav-null fibroblasts
(Figure 6A, red boxes) when compared to ECs and EpCs.
The expression of survivin/BIRC5 was dynamic. At times, the
expression was 15% lower and at other times was more than 20%
higher in fibroblasts. These fluctuations, most likely depend on:
(i) the phase of the cell cycle at the time of cell collection and
lysates preparation, as reported previously (Otaki et al., 2000), (ii)
gene transcriptional status as shown by its upregulation by NFkB
(Mita et al., 2008) or (iii) gene upregulation by the ILGF1/mTor
pathway (Vaira et al., 2007), by c-H-Ras (Sommer et al., 2003),
and Wnt-2 (You et al., 2004). Noticeably, XIAP/BIRC4 was
the only IAP that exhibited striking difference in expression; it
was expressed 2–3 times more in wt-fibroblasts than in ECs.
Furthermore, the expression of XIAP/BIRC4 was 1.5–2 greater
in the Cav-null fibroblasts than in wt-fibroblasts (Figure 6A,
Figure S3A from Supplementary Data).
Next, we used specific siRNAs to knockdown the first four
BIRCs to evaluate their effects on fibroblast apoptosis. Efficient
knockdown was achieved 72–96 h post-siRNA transfection.
Protein expression was recovered in all cases by 144 h post-
siRNA transfection (Figure 6B). Because the IAPs BIRC-2, 3,
and 4 are thought to control apoptosis (Vaux and Silke, 2003;
Moodley et al., 2004; Larsson et al., 2008; de Almagro and
Vucic, 2012) we knocked down each of them individually or
in pairs and assessed their effect on fibroblast apoptosis using
TUNEL 72 and 96 h later. The knockdown of individual IAPs
did affect the proportion of apoptotic wt-fibroblasts, but it was
statistically significant only for XIAP. XIAP knockdown made
the wt-mouse fibroblasts more sensitive (>35%) to FasL-induced
apoptosis (Figure 6C). The knockdown of BIRC2 (p < 0.38,
Figure 6D) or BIRC3 (p < 0.22, Figure 6E) did not significantly
impact fibroblast apoptosis. To better define the involvement of
IAPs in fibroblast apoptosis, double knockdowns were performed
(Figures 6F,G,H). The TUNEL assay did not indicate any
additive effects on fibroblast apoptosis. In the case of XIAP-IAP1
(Figure 6F) and XIAP-IAP2 double knockdowns (Figure 6H),
the apoptosis-resistance was similar to XIAP knockdown alone,
(35% decrease in fibroblast apoptosis-resistance), while the cIP1-
cIAP2 double knockdown did not exhibit any differences. Thus,
our results demonstrate that the fibroblasts constitutively express
more XIAP, and the involvement of this increased expression in
establishing fibroblast resistance to FasL-induced apoptosis was
more than 35%. It was surprising that XIAP knockdown was
involved only 35% in the apoptosis-resistance to FasL treatment
and we decided to investigate other molecules reported to
participate in fibroblast apoptosis-resistance.
Thus, we examined the expression of other apoptotic proteins
(Bad, Bax, Bcl-2, BclXL, Bak, BimEL, BimL, Bims, and Bid).
Among them, only Bax expression was <20% higher in all
isolated fibroblasts, when compared to the ECs and EpCs
(Figure 7A, boxed area). Because the overexpression and/or
function of Bcl-2 were connected to apoptosis resistance in
rat heart fibroblasts (Mayorga et al., 2004), we investigated
its functionality during FasL triggered apoptosis of mouse
lung fibroblasts using pharmacological inhibition. As shown in
Figures 7E,F, the inhibition of Bcl-2 by ABT-236 (a broad range
inhibitor) did not impact FasL-induced apoptosis. Moreover,
the percentage of induced apoptosis did not differ from the
conditions used throughout the paper (last two columns of
Figure 7F). Pretreatment of isolated mouse lung fibroblasts with
the more specific inhibitor ABT-199 also did not affect FasL-
induced apoptosis (Figure 7E). Thus, our results prove that Bcl-2
is not overexpressed and its functional inhibition does notmodify
the apoptotic resistance of isolated mouse lung fibroblasts.
One of the most exploited Fas-triggered pathway leading
to mitochondrial membrane permeabilization, cytochrome c
release, and apoptosis, involves caspase-8 activation, Bid cleavage
and the translocation of a 15 kDa tBid fragment to the
mitochondrial membrane to facilitate Bax activation (Kantari
and Walczak, 2011). Therefore, we investigated the status of
Bid in the isolated fibroblasts after FasL-treatment. While the
expression of Bid was the same in all lung cell types investigated
(Figure 7A) after FasL treatment, we consistently detected the 15
kDa fragment Bid cleavage product, after 1 h. We were able to
detect this fragment beyond 24 h (Figure 7C).
It has been suggested that fibroblast resistance to apoptosis is
mediated byDDR1 (Matsuyama et al., 2007), FasL (Kuwano et al.,
2002; Moodley et al., 2004; Larsson et al., 2008; Kopinski et al.,
2011) and c-FLIP (Safa, 2012), therefore we also explored their
presence in the isolated fibroblasts and compared their levels to
those measured in ECs and EpCs. We found that the expression
of all three proteins was constitutively modified (Figure 7B).
FasL, bound to the cell membrane was downregulated in each
of the fibroblasts types (red rectangle in upper panel from
Figure 7B). DDR1 expression in the wt-fibroblasts did not differ
from the ECs and EpCs, while a 2- to 3-fold increase in expression
was observed in the Cav-null fibroblasts (red boxed area in
second panel). c-FLIP expression was augmented in all fibroblasts
(1.5-fold increase in wt-fibroblasts vs. the EpCs and ECs and
>2-fold increase in Cav-null fibroblasts vs. wt-fibroblasts, red
bounded area in the third panel of Figure 7B and Figure S3B
from Supplementary Data.
As in the case of individual IAPs we knockdown the DDR1
using specific siRNA, and found that its influence in fibroblast
apoptosis resistance, detected by the TUNEL assay, was less
<10% and remained in the same range (around 10%) even when
double knockdown with BIRC1 and BIRC2 and BIRC5/XIAP
were tried (not shown). Thus, we silenced c-FLIP and the results
follow.
Knockdown of c-FLIP expression was transitory. Maximal
downregulation occurred after 96 h (>85%) in all of the
fibroblast types and full recovery was achieved after 144 h
(Figure 7). The sensitivity of fibroblasts to apoptosis increased
by >35% after c-FLIP knockdown (Figure 7D), while double
XIAP/c-FLIP knockdown increased the sensitivity to FasL
treatment in fibroblast by almost 80% (Figure 7E). Based on
these data we concluded that the apoptosis resistance of lung
fibroblasts to FasL-induced apoptosis was more than 80%
dependent on XIAP and c-FLIP expression, while the presence
of other molecular signatures such as DDR1, p53, sFas and the
activation/deactivation status of other survival pathways explain
the remaining 20%.
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FIGURE 7 | Contribution of Bcl-2 family members, cFLIP, and XIAP to fibroblasts’ increased resistance to apoptosis. Protein expression of seven members
of Bcl-2 family of apoptotic proteins shows that in different types of lung cellular populations, only Bax is constitutively overexpressed (red box); n = 5 for each type of
(Continued)
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FIGURE 7 | Continued
cells. (B) Expression of other apoptotic proteins, in the same types of isolated cells showing (red rectangles): FasL downregulation, DDR1 upregulation–especially in
Cav-null fibroblasts, and cFLIP upregulation in all fibroblasts; n = 5 for each type of cells. (C) Presence of cleaved form of Bid (15 kD fragment on isolated fibroblasts
treated with FasL and CHM), is easily detected with a specific anti tBid Ab; n = 7 for each time point. (D) The transitory effect of siRNA silencing of cFLIP showing its
temporary down regulation between 72 and 120 h; n = 5 for each type of fibroblasts and every time point. (E) Pharmacologic inhibition of Bcl-2 (E,F) shows no effect
on fibroblasts resistance to apoptosis by the broad specific ABT-236 (F) or by the more specific ABT-199 (E) as detected by the TUNEL reaction; n = 8 for every type
of fibroblast, *p < 0.3. However, †p < 0.001 when the fibroblasts were treated with FasL + CHM even in the presence of ABT-236; n = 6 for every type of fibroblasts
and the experiments were repeated three times. (G) Increased apoptotic susceptibility of cells to FasL in cFLIP knockdown fibroblasts; n = 7, *p < 0.01 when
compared with the controls and †p < 0.05 in between wt and cav-null fibroblasts. (H) Double XIAP/ cFLIP knockdown shows an additive effect on apoptosis
resistance to FasL treatment. n = 7, *p < 0.05 when compared to control and †p < 0.01 in between wt and Cav-null fibroblasts.
DISCUSSION
Apoptosis is the best characterized process of programmed
cell death that results in the demise of the cell without
the activation of innate immune responses (Danial and
Korsmeyer, 2004). Since cell death was first described in
the 1960s, a number of different death mechanisms have
been described and classified, based on both morphological
and biochemical criteria. Apoptosis, a controlled cessation of
cellular processes, is characterized at the cellular level by cell
shrinkage, nuclear condensation/fragmentation, and membrane
vesiculation/blebbing (Wolfs et al., 2005). The activation of the
Fas receptor induces apoptosis in vivo in cell types that include
hepatocytes, lymphoid, endothelial, and glomerular and lung
epithelial cells (Matute-Bello et al., 2001; Janin et al., 2002).
Our study determined that lungmouse fibroblasts are resistant
to FasL ligation unless CHM is added, as previously reported
in human fibroblasts (Tepper et al., 2000; Santiago et al., 2004).
We also show that lung mouse fibroblasts respond differently
to another apoptosis inducer –TNF-α. Even if TNF-receptor1
(TNFR1) and FasL use homologs signaling pathways, we suggest
that the dissimilarity arises because the two receptors utilize
different proximal signaling molecules to activate the caspase
pathway. TNFR1 requires the adapters: Tumor necrosis factor
receptor type 1-associated DEATH domain protein (TRADD)
and receptor interacting protein (RIP) to transduce signals to
the Fas-Associated protein with Death Domain (FADD) and the
downstream caspase 8. The fine tuning of the responses mediated
by the TNF-receptor 1 are regulated by its internalization as long
as its compartmentalization dictates which signaling pathways
used by the receptor are utilized. The pro-apoptotic signaling
emanates primarily from intracellular vesicles and requires
receptor internalization, whereas the non-apoptotic signaling
could start at the plasma membrane and it was shown that only
late steps in receptor signaling are internalization dependent. Our
data suggest that the differences in response of isolated fibroblasts
to FasL and TNF could be explained by the way in which the two
receptors signal.
Activation of Fas receptor (FasR), triggers apoptotic, and non-
apoptotic signaling pathways that diverge at the plasmalemma
level. The FasR, a “FADD-only” recruiting molecule does not
require TRADD or RIP for signaling. Instead, FasR can interact
directly with FADD, leading to the activation of caspase 8
inside of the newly formed DISC, as our data suggest that
happens in the murine lung fibroblasts. FasL binds to the CD95,
localized in membrane rafts, where starts to form stable FasR
micro-aggregates which coalesce into larger signaling platforms.
At this level the apoptosis and no-apoptosis signaling pathways
are separated. The apoptosis signaling complexes need to be
internalized into the endosomal compartment where high levels
of active DISC are found. Inside the DISC caspase-8 dimerize
and this is the first step in the activation of this protease, then
the active molecule is converted in its mature heterotetrameric
form by auto-proteolytic maturation and finally is released from
the DISC. Active caspase-8 initiates the apoptotic cascade. Thus,
the two receptors are using same basic signaling molecule but in
a very different combination which is fine tuned for specificity,
intensity and length of response by additional molecules. These
fine tuners are the molecules making the difference in the
response of the two receptors.
Importantly, the time needed for wt-fibroblasts or Cav-null
fibroblasts to undergo FasL-mediated apoptosis was 6–7 h, a
result that is in agreement with previously published work on
different cell types (Duke et al., 1986) and human fibroblasts. In
this context, our data demonstrate that the resistance to apoptosis
of Cav-null fibroblasts depends not only on the expression of
anti-apoptotic proteins, but also on the increased production of
sFas which still plays a small role in the anti-apoptotic process.
These findings are similar to those reported in human fibroblasts
isolated from IPF patients (Moodley et al., 2004; Buhling et al.,
2005). Studies of human IPF have established that decreased
apoptosis of modified fibroblasts/myofibroblasts plays a role in
the persistence of fibrotic lesions leading to organ dysfunction
(Barbas-Filho et al., 2001; Buhling et al., 2005; Plataki et al., 2005).
Our data, spanning over 9 months, also indicate that the Cav-null
fibroblasts/myofibroblasts are present at all times inmurine lungs
that display a fibrotic phenotype.
Both morphological changes (Moodley et al., 2004;
Thannickal and Horowitz, 2006) and common biochemical
markers (Tanaka et al., 2002; Moodley et al., 2004; Wynes
et al., 2011; Ajayi et al., 2013) were examined during human
IPF fibroblast apoptosis; however, few studies have examined
apoptosis in mouse lung fibroblasts (Moodley et al., 2004)
as this field is still an active area of investigation. We report
that the number of wt-fibroblasts undergoing FasL-induced
apoptosis was significantly higher than in Cav-null fibroblasts.
These findings indicate an increased resistance to apoptosis in
Cav-null fibroblasts. In addition, isolated Cav-null fibroblasts
had a greater proportion of α-SMA-positive cells than the
wt-fibroblasts, suggesting an increase in myofibroblasts-like
cells. However, the presence of a constitutively increased number
of myofibroblasts may reflect a more rigid environment rather
Frontiers in Physiology | www.frontiersin.org 17 March 2017 | Volume 8 | Article 128
Predescu et al. Caveolin Driven Resistance to Apoptosis
than a mechanism of apoptosis resistance. Previous studies
have shown that apoptosis-resistance in myofibroblasts it is not
necessarily correlated with their organization/quantity of α-SMA
(Jelaska and Korn, 2000). Moreover, during wound healing,
both myofibroblasts and endothelial cells are eliminated via
apoptosis suggesting that the myofibroblast is not intrinsically
apoptosis-resistant. It may become resistant under the influence
of local factors, as in IPF, or genetic factors, as in our case, which
affects the basic mechanisms of apoptotic pathways triggered by
a modified environment.
Themain changes of the cellular surface during apoptosis were
cell shrinkage, the formation of filopodia, blebbing and increased
PS expression. Cell shrinkage was the earliest change, starting 30
min after FasL, indicating that apoptotic cell death is coupled
to normotonic cell shrinkage, termed apoptotic volume decrease
(AVD). AVD has been observed when death receptors, such as
CD95, are engaged in human lymphoid (U937), human epithelial
(HeLa), mouse neuroblastoma/rat glioma hybrid (NG108-15),
and rat phaeochromocytoma (PC12) cells (Okada and Maeno,
2001) and in mouse fibroblasts as demonstrated by the present
study. AVD is an early apoptotic process that initially preserves
to some extent, the cell’s energetic status enabling the apoptotic
machinery to work properly (Mills et al., 1999). Our data
show that cell shrinkage is not a caspase-dependent process,
finding consistent with previous studies (Barros et al., 2002;
Moodley et al., 2004). After FasL stimulation, retraction of
cellular filopodia was detected after AVD. Notably, the number
of filopodia was higher in the Cav-null phenotype, probably
reflecting activation status of these cells that coincided with
the increased expression of PS on the external leaflet of the
plasmalemma proper at 1 h. The externalization of PS peaked at
∼3 h and coincided with the initiation of membrane blebbing.
It was shown that overexpression of B-cell lymphoma (Bcl-2)
proteins completely abolishes membrane blebbing induced by
Fas stimulation (extrinsic pathway; Nunez et al., 2010). Based
on these findings we assessed its expression in different lung
cell populations and found that the expression did not differ
between the cell types studied, or between the different lung
mouse fibroblasts. These data suggests that Bcl-2 is not an
apoptotic molecule in lung fibroblasts. Based on the fact that
Bcl-2 overexpression was shown to be involved in rat heart
fibroblasts resistance to different apoptotic stimuli (Mayorga
et al., 2004), we examined the role of Bcl-2 in apoptotic resistance
to FasL by inhibiting its functionality pharmacologically using
two Bcl-2 inhibitors. These inhibitors include ABT-263, which
inhibits three out of the four members of the Bcl-2 family
(BclXL, Bcl-2, and Bcl-w) and ABT-199, a more selective Bcl-
2 inhibitor. The inhibition of Bcl-2 revealed that Bcl-2 is not
involved in murine lung fibroblast resistance to FasL-induced
apoptosis. The participation of the other two members of this
family (MCL1 and BFL1/A), in the response of lung fibroblasts
to FasL-induced apoptosis requires further studies and are under
scrutiny. Because the expression levels of Bcl-2 and the response
of fibroblasts to FasL did not change after its inhibition we
concluded that Bcl-2 and at least other members of this family
of anti-apoptotic proteins do not participate in mouse lung
fibroblast resistance to apoptosis.
This chain of events–AVD, development of filopodia,
externalization of PS and blebbing indicates weakening of
cytoskeleton-membrane interactions, even if a delayed change
in the course of apoptosis at the beginning of apoptotic body
formation occurs (Coleman et al., 2001). Almost within the
same time frame as the events described above, we detected
the presence of cytoskeletal bundles, surfacing of M30 positive
lasting for more than 5 h. Their disappearance overlapped, first
with nuclear condensation and then with the fragmentation of
apoptotic cells into apoptotic bodies. Detection of cleaved K-
18 by M30 Ab was evident after 3 h in Cav-null fibroblasts
whereas its exposure started after 50 min in wt-fibroblasts.
Interestingly, the presence of K-18 in unstimulated fibroblasts
was detected in the Cav-null fibroblasts, while its presence
in a few fibroblastic cells in wt-mice reflects the presence of
myofibroblast. Determining the detailed factor(s)/mechanism(s)
triggered by caveolin deficiency responsible for the delayed
cytoskeletal bundle formation is under investigation in our
laboratory and beyond the scope of this work.
The changes in cellular organelles during FasL-triggered
apoptosis were also important, but not as important as the
cytoplasmic changes. Significant changes were recorded in the
status of mitochondrial continuum of isolated murine fibroblasts
after FasL treatment.Mitochondria are dynamic organelles which
fuse and divide continuously (Martinou and Youle, 2011),
thus their extensive fragmentation (fission) is a constant in
apoptosis. Mitochondria integrate death signals through Bcl-2
family members while coordinating caspase activation through
apoptogenic factors like cytochrome c. Mitochondrial changes
start as alterations in mitochondrial membrane potential that
terminate with membrane permeabilization. At the same time,
mitochondria fragment and their internal ultrastructure is
altered as a result of an activation of the fission machinery
and concomitant neutralization of the fusion machinery. The
release of tBid, event documented in our isolated fibroblasts,
triggers Bax/Bak activation which correlates with a reduction in
mitochondrial fusion leading to mitochondrial fragmentation, as
indicated by our results. While the association of mitochondria
with the endoplasmic reticulum (ER) is important for the transfer
of phospholipids and calcium, an extensive mitochondrial
fragmentation will enhance these processes and facilitate calcium
accumulation in the mitochondrial matrix leading to cell death.
The sequestered calcium interacts with cyclophilin D to induce
opening of the mitochondrial permeability transition pore (Jeong
and Seol, 2008), membrane permeabilization and fragmentation.
Our results are suggestive of such events; we are reporting
extensive mitochondrial fragmentation and modifications of ER.
Both the Golgi apparatus and the smooth ER were dilated
after FasL stimulation. These changes were more dramatic in
the Cav-null fibroblasts, particularly in the Cav1−/− fibroblasts.
Considering the undeniable evidence for the participation of
ER stress in epithelial apoptosis (Kropski et al., 2013), the
available data regarding the participation of fibroblast ER
in apoptosis are sparse. Even if our data implies that the
observed changes in the ER structure found in all of the
fibroblast types, are somehow involved in the modification of
their apoptotic behavior, more work is necessary to determine
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the participation of ER stress in caveolin driven fibroblast’
fibrosis.
Considering the above characteristic of the apoptotic
process, the data provided in this study reveal that fibroblasts
isolated from wt- and Cav-null mice share many comparable
morphological features of apoptosis that occur over the same
time period. However, relevant morphological differences
between wt- and Cav-null fibroblasts were noticed: (i)
vacuolization in wt-fibroblasts was much more prominent
and frequent than in Cav-null fibroblasts, (ii) enhanced
filopodia formation as well as increased condensation of the
cellular cytoskeleton was evident in the Cav-null fibroblasts,
(iii) the presence of α-SMA was 10 times higher in the Cav-
null phenotype than in the wt-fibroblasts, suggesting of a
constitutively increased number of myofibroblasts, and (iv) a
higher percentage of positive cells combined with the delayed
formation of M30 antigen in Cav-null fibroblasts. Since our
preliminary findings on murine lung fibroblasts exposed to
FasL (Predescu et al., 2011, 2012) are substantiated by the
work reported here, we may conclude that: (i) wt- and Cav-
null fibroblasts undergo sequential cellular changes and share
comparable morphological features of apoptosis that occur over
the same time period, and (ii) while the Cav-null fibroblasts
are more resistant to apoptosis than the wt-fibroblasts, some
morphological characteristics such as filopodia formation,
delayed cleavage of cytoskeletal bundles and the lack of
vacuolization are specific features of Cav-null phenotype
resistance to apoptosis.
The loss of mitochondrial membrane potential, observed in
the current study, occurred during same time frame as the
activation of caspases-8 and the occurrence of Bid fragmentation
before caspase-3 activation, while PS expression, cytocheratin-
18 cleavage and DNA fragmentation occurred after caspase-
3 activation. Thus, in addition to demonstrating that Cav-
null fibroblasts are less sensitive to FasL-induced apoptosis
than wt-fibroblasts, our data also indicates that several of the
morphological features triggered by FasL-induced apoptosis are
caspase-dependent.
The way in which cells manage the mode of transition
from initiator to execution phase of apoptosis permits their
classification in two distinct types, type I and II. In Type I cells
the activation of effector caspase is strong and swift, sufficient
for robust triggering of death machinery. In Type II cells the
activation of initiator caspases is not strong enough for cell
death initiation; therefore these cells require a mitochondrial
amplification loop for effective activation of apoptosismachinery.
They need the presence of the tBid fragment of BH3-only protein
Bid generated by activated caspase-8. tBid translocate to the outer
mitochondrial membrane (OMM) and allosterically activate Bak.
Subsequent oligomerization of Bak and Bax forms pores in OMM
and allows escape of proapoptotic protein such as cytochrome c,
SMAC/DIABLO etc. The insufficient induction of apoptosis in
Type II cells as a failure to activate enough the initiator caspases
was demonstrated to be the consequence of low cell surface
expression of death receptors (Meng et al., 2011) as CD95, and
the presence of caspase inhibitory molecules as XIAP (Jost et al.,
2009). Our data revealing: (i) low CD95 surface expression, (ii)
high levels of XIAP, (iii) caspase-8 activation, and (iv) the release
of tBid, allowed us to concluded that the isolated murine lung
fibroblasts could and should be classified as Type II cells. Thus,
FasL ligation of CD95 triggers the activation of caspase-8 which
cleaves the Bid protein to generate the 15 KDa fragment. tBid
translocation to the OMM induces Bak/Bax oligomerization and
the formation of mitochondrial pore. At this moment the cells
release, in the cytoplasm, proapoptotic molecules and reach the
point of no return.
In isolated fibroblast we found that the processing of Bid into
tBid is primarily facilitated by caspase-8, the first caspase on the
Fas apoptotic pathway (Li et al., 1998). Thus, the facilitation of
crosstalk between death receptors by activated Bid, and the Bcl-
2 controlled apoptotic pathways, amplifies the caspase cascade
(Kaufmann et al., 2012) as needed in Type II cells. Our data
strongly suggest that this is indeed the case in mouse lung
fibroblasts.
When we investigated the molecules involved in the events
described above, we found that some pro- and mostly anti-
apoptotic molecules were constitutively expressed in wt-
fibroblasts and Cav-null fibroblasts. Only Bax was found to be
expressed at higher levels in all three of the fibroblasts types.
Thus, our data suggests that Bax may participate in the fibrotic
process as described in human IPF.
Of the apoptotic regulatory proteins examined, XIAP and
cFLIP exhibited the most dramatic changes in expression
which were constitutively expressed in fibroblasts (Emblom-
Callahan et al., 2010). Previous work based on the expression
levels only has suggested the increased presence of XIAP as a
possible apoptotic mechanism. Our data support this finding and
provide direct functional evidence (siRNA) of its involvement in
apoptosis resistance in this cell type.
The mouse fibroblasts express seven out of eight IAPs. The
level of XIAP is 2–3 times higher than in other lung cells and 1.5
times higher in the Cav-null fibroblasts when compared to the
wt-fibroblasts. The expression of other IAPs (BIRC1, 2, and 3)
differed in the mouse fibroblasts, but not significantly. It has been
suggested that the variations in survivin (BIRC5) expression is
related to the cell cycle; therefore, its direct participation in the
apoptotic resistance of fibroblasts as described previously (Sisson
et al., 2012) is under scrutiny in our laboratory. Because the
down regulation of XIAP increased the sensitivity of fibroblasts
to FasL by more than 30%, in all three fibroblast cell types, the
apoptosis-resistance of isolated fibroblasts could be explained
in part by the constitutively increased expression of XIAP, as
long as neither the knockdown of BIRC2 and BIRC3 nor the
combined knockdowns with XIAP modifies the cell response
to FasL stimulation. Still, in mouse lung fibroblasts with XIAP
knockdown, the addition of CHM is needed to induce Fas-
mediated apoptosis, albeit at a lower dose (10 µg/mL) than the
one used in normal fibroblasts. Our results regarding the direct
involvement of XIAP in apoptosis-resistance are in agreement
with published data in human fibroblasts (Ajayi et al., 2013)
and with its selective expression within the cells (myofibroblasts)
of fibroblastic foci and not in the overlapping endothelium
(Maher et al., 2010). Our data related to the overexpression
of XIAP in lung fibroblasts lead are consistent with published
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data obtained from T-lymphocytes overexpressing XIAP; BIRC5
protected the cells against FasL-induced apoptosis, even if the
protection is trivial (Kaufmann et al., 2012). Thus, our study
confirms and extends the contribution of XIAP to mouse lung
fibroblasts apoptosis-resistance (our data indicate more than
30% involvement) while demonstrating that other factors are
also involved. We found, in preliminary experiments, that the
knockdown of DDR1 modifies the fibroblast resistance to FasL
only by 11%, as assessed by TUNEL, and thus we continued to
search for molecule with a greater impact and found the XIAP
and the c-FLICE.
We detected the presence of other “key regulator of apoptosis”
-c-FLIP (Ozturk et al., 2012), which was highly expression in
all of the mouse lung fibroblast types, with a greater presence
in the caveolin null phenotype. Furthermore, we established
its participation in fibroblast’ apoptosis-resistance via siRNA-
mediated knockdown. As in the case of XIAP, down-regulation
of c-FLIP increased the sensitivity to FasL-induced apoptosis
by 35%. Their double knockdown was additive. The sensitivity
of mouse fibroblasts to FasL was around 70%, with very low
(<1 µg/mL) amounts of CHM and 80% with low (<5 µg/mL)
amounts of CHMneeded to induce apoptosis. Of note, even if the
increase in apoptotic resistance ofmouse lung fibroblasts after the
XIAP/c-FLIP double knockdown is significant, the existence of
additional mechanisms must explain the remaining 20%. These
mechanisms not expected to be vital, and are likely involved in
the refinement of the cellular response. c-FLIP overexpression in
human lungmyofibroblasts from IPF patients has been correlated
with their increased resistance to apoptosis (Tanaka et al., 2002;
Moodley et al., 2004; Golan-Gerstl et al., 2007); however, a
2010 study (Cha et al., 2010) did not confirm these findings.
Therefore, its role remains controversial. We found that its
down-regulation did affect the mouse fibroblasts similar to what
has been observed in other types of cells (Safa, 2012); c-FLIP
increases the resistance to FasL-induced apoptosis through its
constitutive overexpression.
Our data demonstrates that tBid, a very effective inducer of
mitochondrial pore formation (Ott et al., 2009) coexists with
activated caspase-8 and with cFLIP overexpression in the same
cells. These findings can be attributed to the action(s) of XIAP,
which can directly inhibit caspase-3 and caspase-7 and act at a
later stage (caspase inhibition) in the apoptotic pathway.
Based on our results, we are confident that the constitutive
overexpression of BIRC5/XIAP and c-FLIP along with their
molecular mechanisms represent the primary mechanism of
documented mouse lung fibroblast apoptotic resistance.
Our findings regarding the molecular machinery involved in
the apoptosis of mouse fibroblasts induced by FasL demonstrated
that: (i) there is association between the dynamic succession
of morphological changes and commonly used biochemical
markers of induced apoptosis, (ii) of all the IAPs, XIAP
is the primary contributor through its direct inhibition of
executioner caspases, (iii) c-FLIP, as a master regulator of
apoptosis, participates in fibroblast apoptosis resistance with the
same effectiveness (35%) as XIAP, (iv) caspase-8, and caspase-3
along with caspase-9-albeit to a lesser extent–are the executing
molecules, (v) by activating Bid caspase-8 enables the crosstalk
between the extrinsic and the intrinsic apoptotic pathways; thus
the mouse myofibroblasts from the wt- and Cav-null phenotype
could be considered type II cells (Kaufmann et al., 2012) as–
they depend on this crosstalk in order for their mitochondria to
be affected, (vi) even if the constitutive increase in XIAP-cFLIP
is the primary mechanism of fibroblasts resistance to apoptosis,
other fine tuning mechanisms (DDR1 and sFas) cannot be
disregarded.
Thus, our study extends the existing data by showing that
both Cav1−/− (Drab et al., 2001; Razani et al., 2001) and
Cav2−/− (Razani et al., 2002) mice have increased deposition
of extracellular matrix in the alveolar septa, by substantiating
that the main cells responsible are the fibroblasts/myofibroblasts-
the cells that do not want to die-, and by providing in depth
molecular evidence to explain their constitutive resistance to
apoptosis.
In conclusion: (i) the fibroblast is the most apoptosis resistant
cell in mouse lungs, (ii) the lack of caveolins accentuates
this characteristic via specific biochemical, structural, and
phenotypic changes that are similar to those used by the
wt fibroblasts but more accentuated in this background, (iii)
the structural differences between cav1 null and cav2 null
phenotypes (a total lack of cav1 and caveolae in Cav1−/−
mice) does not account for the major differences in their
response to Fas triggered apoptosis even if signaling via other
growth factors and cytokines may differ, and (iv) salient
differences between caveolin null fibroblasts underline the
adaptive phenotypic capacity for some cellular responses, such
as apoptosis resistance, while making it clear that the caveolae
are dispensable for a minimal functional adaptability to a certain
extent.
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